Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Harris NL. Mantle cell lymphoma. J Clin Oncol. 1994;12:876–877.
   PubMed Web of Science ®Google Scholar
• Martin P, Coleman M, Leonard JP. Progress in mantle-cell lymphoma. J Clin Oncol. 2009;27:481–483.
   PubMed Web of Science ®Google Scholar
• Williams ME, Bernstein SH, Jares P, et al. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2013;54:1882–1890.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416–3423.
   PubMed Web of Science ®Google Scholar
• Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302–4310.
   PubMed Web of Science ®Google Scholar
• Parekh S, Weniger MA, Wiestner A. New molecular targets in mantle cell lymphoma. Semin Cancer Biol. 2011;21:335–346.
   PubMed Web of Science ®Google Scholar
• Dave BJ, Hess MM, Pickering DL, et al. Rearrangements of chromosome band 1p36 in non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:1401–1409.
   PubMed Web of Science ®Google Scholar
• Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49:439–451.
   PubMed Web of Science ®Google Scholar
• Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006;24:805–815.
   PubMed Web of Science ®Google Scholar
• Collavin L, Lunardi A, Del SG. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17:901–911.
   PubMed Web of Science ®Google Scholar
• Bailey SG, Cragg MS, Townsend PA. Family friction as ΔNp73 antagonises p73 and p53. Int J Biochem Cell Biol. 2011;43:482–486.
   PubMed Web of Science ®Google Scholar
• Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–252.
   PubMed Web of Science ®Google Scholar
• Han JA, Kim JI, Ongusaha PP, et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 2002;21:5635–5644.
   PubMed Web of Science ®Google Scholar
• Lau L, Hansford LM, Cheng LS, et al. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene. 2007;26:1920–1931.
   PubMed Web of Science ®Google Scholar
• Lau LM, Wolter JK, Lau JT, et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene. 2009;28:2024–2033.
   PubMed Web of Science ®Google Scholar
• Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia. 1997;11:64–72.
   PubMed Web of Science ®Google Scholar
• Melo JV, Brito-Babapulle V, Foroni L, et al. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int J Cancer. 1986;38:531–538.
   PubMed Web of Science ®Google Scholar
• Jeon HJ, Kim CW, Yoshino T, et al. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102:1323–1326.
   PubMed Web of Science ®Google Scholar
• Lai R, McDonnell TJ, O'Connor SL, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002;26:849–855.
   PubMed Web of Science ®Google Scholar
• Ahrens AK, Chaturvedi NK, Nordgren TM, et al. Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites. Leuk Lymphoma. 2012;53:2269–2278.
   PubMed Web of Science ®Google Scholar
• Hegde GV, Nordgren TM, Munger CM, et al. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. Int J Cancer. 2012;131:2951–2960.
   PubMed Web of Science ®Google Scholar
• Irwin M, Marin MC, Phillips AC, et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000;40738:648.
   Google Scholar
• Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2012;87:604–609.
   PubMed Web of Science ®Google Scholar
• Irwin MS, Kondo K, Marin MC Jr, et al. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403–410.
   PubMed Web of Science ®Google Scholar
• Kopp KL, Dabelsteen S, Krejsgaard T, et al. COX-2 is a novel target in therapy of mycosis fungoides. Leukemia. 2010;24:2127–2129.
   PubMed Web of Science ®Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–1102.
   PubMed Web of Science ®Google Scholar
• Lunghi P, Costanzo A, Mazzera L, et al. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res. 2009;15:6495–6502.
   PubMed Web of Science ®Google Scholar
• Luh LM, Kehrloesser S, Deutsch GB, et al. Analysis of the oligomeric state and transactivation potential of TAp73α. Cell Death Differ. 2013;20:1008–1016.
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091.
   PubMed Web of Science ®Google Scholar
• Roller DG, Axelrod M, Capaldo BJ, et al. Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther. 2012;11:2505–2515.
   PubMed Web of Science ®Google Scholar
• Wang J, Hughes TP, Kok CH, et al. Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. Br J Cancer. 2012;106:1772–1778.
   PubMed Web of Science ®Google Scholar
• Chirasani SR, Leukel P, Gottfried E, et al. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. Int J Cancer. 2013;132:843–853.
   PubMed Web of Science ®Google Scholar
• Gottfried E, Lang SA, Renner K, et al. New aspects of an old drug-diclofenac targets MYC and glucose metabolism in tumor cells. PLoS One. 2013;8:e66987.
   PubMed Web of Science ®Google Scholar
• Braun FK, Al-Yacoub N, Plotz M, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol. 2012;132:429–439.
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700–714.
   PubMed Web of Science ®Google Scholar
• Long JS, Ryan KM. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene. 2012;31:5045–5060.
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803–1815.
   PubMed Web of Science ®Google Scholar
• Gillis LD, Leidal AM, Hill R, et al. p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle. 2009;8:253–256.
   PubMed Web of Science ®Google Scholar
• Lu JV, Walsh CM. Programmed necrosis and autophagy in immune function. Immunol Rev. 2012;249:205–217.
   PubMed Web of Science ®Google Scholar
• Silke J, Strasser A. The FLIP side of life. Sci Signal. 2013;6:e2.
   Web of Science ®Google Scholar
• Vaseva AV, Marchenko ND, Ji K, et al. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell. 2012;149:1536–1548.
   PubMed Web of Science ®Google Scholar
• Roue G, Perez-Galan P, Lopez-Guerra M, et al. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol. 2007;178:1923–1930.
   PubMed Web of Science ®Google Scholar